MedTrace Logo

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

NCT05676931 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-10-02

No results posted yet for this study

Summary

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.

Conditions

Interventions

DRUG

Domvanalimab

Administered as specified in the treatment arm

DRUG

Quemliclustat

Administered as specified in the treatment arm

DRUG

Zimberelimab

Administered as specified in the treatment arm

DRUG

Docetaxel

Administered as specified in the treatment arm

DRUG

Platinum-Based Doublet

Administered as specified in the treatment arm

Sponsors & Collaborators

  • Arcus Biosciences, Inc.

    collaborator INDUSTRY

  • Gilead Sciences

    lead INDUSTRY

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-21
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Georgia
  • Italy
  • Poland
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05676931 on ClinicalTrials.gov